AB0838 The efficacy of adalimumab and sulfasalazine in alleviating axial and aortic inflammation detected in pet/ct in patients with axial spondyloarthritis. (12th June 2018)

• Record Type: Journal Article
• Authors: Kaijasilta, J.-P.; Kerola, A.; Tuompo, R.; Kauppi, M.; Relas, H.; Loimaala, A.; Koivu, H.; Schildt, J.; Kerola, T.; Eklund, K.; Nieminen, T.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 1547
• Page End: 1547
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.4627
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Inflammatory pathways are likely the central link from axial spondyloarthritis to the known increased risk of cardiovascular morbidity. Literature on positron emission tomography imaging together with computed tomography (PET/CT) in the context of spondyloarthritis is limited. Objectives: The aim was to grade the inflammatory signals in the sacroiliac joints and aorta in the PET/CT imaging before and after antirheumatic treatment of clinically active axial spondyloarthritis with either sulfasalazine (SSZ), the firstline antirheumatic drug in Finland for axial spondyloarthritis, or adalimumab (ADA). Methods: Fourteen patients aged 18–75 years with axial spondyloarthritis and radiologic sacroiliitis as detected either by MRI or X-ray and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and visual analogue scale (VAS)≥4 have been recruited to the pilot study. DMARD-naïve patients started SSZ for 12 weeks. Those who failed to reach remission (BASDAI and VAS≥4) with SSZ or were known to be resistant to conventional DMARDs before inclusion, adalimumab was started for 16 weeks. The patients were scanned with 18F-fluorodeoxyglucose (FDG) PET/CT after inclusion and after treatment with SSZ and/or ADA. Target-to-background ratio (TBR) was assessed from the aortic root to abdominal aorta as well as for the sacroiliac joints. For statistical comparisons before and after antirheumatic treatment, paired t-test was used. Mean ±SD are shown. Results: Our pilot study comprised of nine patients with ADA and five with SSZ. In the SSZ patients (three men, age 36.0±13.4 years), mean BASDAI was 4.7±1.6 before and 3.4±1.8 after the treatment (p=0.091). In the ADA patients (six men, age 35.1±9.8 years), BASDAI decreased from 4.9±1.2 to 2.3±1.8 (p=0.004). Among the SSZ patients, maximal TBR in sacroiliac joints declined from 2.35±0.55 to 1.51±0.22 (-35.8%, p=0.03) (figure 1). Aortic maximal TBR declined from 2.44±0.46 to 2.07±0.43 (-15.0%, p=0.23). In the ADA patients, maximal TBR in sacroiliac joints was 1.89±0.37 before and 1.90±0.51 after treatment (+0.3%, p=0.97), and in aorta 2.15±0.54 before and 2.37±0.53 after treatment (+10.4%, p=0.19). Conclusions: As detected by reduced 18F-FDG uptake, SSZ reduced inflammation in sacroiliac joints. There was also clear trend towards reduction of inflammation in aorta. ADA and SSZ both reduced clinical symptoms, but only ADA reached statistical significance. PET/CT could not show any reduction in FDG uptake in the ADA group. This may be due to the fact that ADA was used as the second line treatment, when the inflammation had already been reduced to the limit detectable by the method. Acknowledgements: This study was funded by Abbvie inc. Disclosure of Interest: J.-P. Kaijasilta: None declared, A. Kerola: None declared, R. Tuompo: None declared, M. Kauppi: None declared, H. Relas: None declared, A. Loimaala: None declared, H. Koivu: None declared, J. Schildt: None declared, T. Kerola: None declared, K. Eklund: None declared, T. Nieminen Grant/research support from: Abbvie Inc